Kevin Conroy (Exact Sciences)

A month af­ter Il­lu­mi­na's big Grail buy­out, Ex­act Sci­ences scoops up liq­uid biop­sy ri­val Thrive for a rel­a­tive bar­gain

Il­lu­mi­na is go­ing to have a lot of work to do to prove Grail was worth those $8 bil­lion.

To­day, Ex­act Sci­ences an­nounced that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA